Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ATG7 | O95352 | 3/20 | 0.38 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.37 |
| ▸ | MARS1 | P56192 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18950207 | 0.95 | HSPA5 (0.43) | HSPA5ADORA3ATG7ENTPD1 | |
| SCHEMBL18852628 | 0.92 | ADK (0.43) | HSPA5ADORA3ATG7PRKACAHSPA2 | |
| SCHEMBL17472296 | 0.90 | HSPA8 (0.45) | HSPA5ADORA3 | |
| SCHEMBL21244328 | 0.89 | ENTPD1 (0.41) | HSPA5ADORA3ENTPD1 | |
| SCHEMBL15746955 | 0.84 | HSPA5 (0.45) | HSPA5ADORA3ATG7 | |
| SCHEMBL18531148 | 0.82 | ENTPD1 (0.41) | HSPA5ADORA3ENTPD1 | |
| SCHEMBL19007434 | 0.79 | HSPA5 (0.46) | HSPA5ADORA3ATG7 | |
| SCHEMBL12369365 | 0.79 | ATG7 (0.36) | ADORA3ATG7 | |
| SCHEMBL18464494 | 0.76 | ADK (0.51) | HSPA5ADORA3ATG7 | |
| SCHEMBL22315144 | 0.73 | ADORA3 (0.51) | HSPA5ADORA3ENTPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814760-B2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | HSPA5 2318/4885ADORA3 103/4885ATG7 3303/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | HSPA5 1076/4885ADORA3 406/4885ATG7 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.